Azacyclic compounds
US-9296694-B2 · Mar 29, 2016 · US
Methods for the treatment of parkinson's disease psychosis using pimavanserin
US9446037B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9446037-B2 |
| Application number | US-201314647438-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 26, 2013 |
| Priority date | Nov 27, 2012 |
| Publication date | Sep 20, 2016 |
| Grant date | Sep 20, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for excluding from a clinical study patients with likelihood for placebo response, the method comprising screening a group of psychosis patients by administering social interaction therapy designed for psychosis, wherein patients who respond sufficiently to the social interaction therapy are excluded from a subsequent clinical study. 2. The method according to claim 1 , wherein the social interaction therapy is administered one day to two weeks. 3. The method according to claim 1 , wherein the social interaction therapy is a brief psycho-social therapy. 4. The method according to claim 1 , wherein the patients are Parkinson's disease psychosis patients. 5. The method according to claim 1 , wherein the social interaction therapy is a non-pharmaceutical therapy. 6. The method according to claim 1 , wherein the method is integrated in a clinical trial for psychosis patients. 7. The method according to claim 6 , wherein the psychosis patients are Parkinson's disease psychosis patients. 8. A method for improvement of daytime wakefulness in a Parkinson's disease patient, comprising the oral administration of pimavanserin, or a pharmaceutically acceptable salt thereof, to the patient in a daily dose of about 40 mg, wherein the improvement of wakefulness is measured on the Scales for Outcomes in Parkinson's Disease—Sleep scale. 9. The method according to claim 8 , wherein the improvement of daytime wakefulness is more than 20% compared to baseline after oral administration of pimavanserin, or a pharmaceutically acceptable salt, after 43 days. 10. The method according to claim 8 , wherein the improvement of daytime wakefulness is about 29% compared to baseline after oral administration of pimavanserin, or a pharmaceutically acceptable salt, after 43 days.
Assignees
Inventors
Classifications
Ketones · CPC title
Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin · CPC title
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
Amines {(A61K31/04 takes precedence)} · CPC title
of the multiple-choice answer type, i.e. where a given question is provided with a series of answers and a choice has to be made · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9446037B2 cover?
- Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin.
- Who is the assignee on this patent?
- Acadia Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4468. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).